OPNT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
OPNT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Opiant Pharmaceuticals's change in inventory for the quarter that ended in Sep. 2022 was $0.00 Mil. It means Opiant Pharmaceuticals's inventory stayed the same from Jun. 2022 to Sep. 2022 .
Opiant Pharmaceuticals's change in inventory for the fiscal year that ended in Dec. 2021 was $0.00 Mil. It means Opiant Pharmaceuticals's inventory stayed the same from Dec. 2020 to Dec. 2021 .
Opiant Pharmaceuticals's Total Inventories for the quarter that ended in Sep. 2022 was $0.00 Mil.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
The historical data trend for Opiant Pharmaceuticals's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Opiant Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Jul12 | Jul13 | Jul14 | Jul15 | Jul16 | Jul17 | Dec18 | Dec19 | Dec20 | Dec21 | |||||||||||
Change In Inventory | Get a 7-Day Free Trial | - | - | - | - | - |
Opiant Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Oct17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | |
Change In Inventory | Get a 7-Day Free Trial | - | - | - | - | - |
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Opiant Pharmaceuticals (NAS:OPNT) Change In Inventory Explanation
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Opiant Pharmaceuticals's Days Inventory for the quarter that ended in is calculated as:
Days Inventory | = | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period |
= | 0 | / | 0 | * | 365 / 4 | |
= | N/A |
2. Inventory Turnover measures how fast the company turns over its inventory within a year.
Opiant Pharmaceuticals's Inventory Turnover for the quarter that ended in Sep. 2022 is calculated as
Inventory Turnover | = | Cost of Goods Sold | / | Average Total Inventories |
= | 0 | / | 0 | |
= | N/A |
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Opiant Pharmaceuticals's Inventory to Revenue for the quarter that ended in Sep. 2022 is calculated as
Inventory-to-Revenue | = | Average Total Inventories | / | Revenue |
= | 0 | / | 0 | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Opiant Pharmaceuticals's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
David D O'toole | officer: Chief Financial Officer | 1640 MARENGO STREET, LOS ANGELES CA 90033 |
Ellison Mark Jason Heath | other: UK Managing Director | C/O OPIANT PHARMACEUTICALS, INC., 201 SANTA MONICA BLVD., SUITE 500, SANTA MONICA CA 90401 |
Roger Crystal | director, 10 percent owner, officer: Chief Executive Officer | 445 PARK AVE, 10TH FL., NEW YORK NY 10022 |
Phil Skolnick | officer: Chief Scientific Officer | C/O DOV PHARMACEUTICAL, INC., 433 HACKENSACK AVENUE, HACKENSACK NJ 07601 |
Brian Gorman | other: General Counsel | 233 WILSHIRE BLVD, SUITE 280, SANTA MONICA CA 90401 |
Matthew R. Ruth | officer: Chief Commercial Officer | 233 WILSHIRE BLVD., SUITE 280, SANTA MONICA CA 90401 |
Michael Sinclair | director, 10 percent owner, officer: Executive Chairman | 86 GLOUCESTER PLACE, LONDON XX W1U6HP |
Craig A Collard | director | C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518 |
Ann L. Macdougall | director | C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401 |
Thomas T. Thomas | director | C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401 |
Masuoka K. Lorianne | director | C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070 |
Gabrielle Alison Silver | director | C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401 |
Rahsaan Thompson | other: General Counsel | 233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401 |
Aziz Mottiwala | officer: Chief Commercial Officer | 233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401 |
Richard J Daly | director | 355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134 |
From GuruFocus
By PRNewswire PRNewswire • 11-25-2022
By GuruFocusNews GuruFocusNews • 07-09-2022
By Business Wire Business Wire • 01-07-2023
By Value_Insider Value_Insider • 10-27-2022
By PRNewswire PRNewswire • 11-14-2022
By PRNewswire PRNewswire • 11-22-2022
By Stock market mentor Stock market mentor • 01-19-2023
By Stock market mentor Stock market mentor • 02-06-2023
By Stock market mentor Stock market mentor • 01-08-2023
By PurpleRose PurpleRose • 08-01-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.